[1] Frank A Sloan, Hellen Gelband, Cancer Control Opportunities in Low- and Middle- Income Countries. Washington (DC): National Academies Press (US); 2007.
[2] Soerjomataram I, Bray F. Planning for tomorrow: global cancer incidence and the role of prevention 2020-2070. Nat Rev Clin Oncol, 2021; 18: 663-72.
[3] Salas-Benito D, Perez-Gracia JL, Ponz-Savise M, et al. Paradigms on immunotherapy combinations with chemotherapy. Cancer Discovery, 2021; 11: 1353-67.
[4] Cecilia C Ayala-Aguilera, Teresa Valero, Alvaro Lorente-Macias, et al. Small Molecule Kinase Inhibitor Drugs (1995–2021): Medical Indication, Pharmacology, and Synthesis. J. Med. Chem. 2022, 65, 2, 1047–1131
[5] Esteban-Villarrubia J, Soto-Castillo JJ, Pozas J. etc. Tyrosine Kinase Receptor in Oncology. Int J Mol Sci. 2020. Nov 12;21(22):8529.
[6] Robert Roskoski Jr. The ErbB/HER family of protein-tyrosine kinases and cancer. Pharmacol Res. 2014 Jan;79:34-74.
[7] Cersosimo, R.J. Gefitinib: An adverse effects profile. Expert Opin. Drug Saf. 2006, 5, 469– 479.
[8] Paech, F.; Bouitbir, J.; Krahenbuhl, S. Hepatocellular Toxicity Associated with Tyrosine Kinase Inhibitors: Mitochondrial Damage and Inhibition of Glycolysis. Front. Pharmacol. 2017, 8, 367.
[9] Jabbour, E.; Deininger, M.; Hochhaus, A. Management of adverse events associated with tyrosine kinase inhibitors in the treatment of chronic myeloid leukemia. Leukemia 2011, 25, 201–210.
[10] Characterization of Therapeutic Monoclonal Antibodies. 18 January, 2021
[11] Rebecca S. Goydel, Christoph Rader. Antibody-based cancer therapy. Oncogene. 2021. 40:3655–3664.
[12] Salas-Benito D, Perez-Gracia JL, Ponz-Savise M, et al. Paradigms on immunotherapy combinations with chemotherapy. Cancer Discovery, 2021; 11: 1353-67.
[13] Baselga J, Swain SM. Novel anticancer targets: Revisiting ERBB2 and ERBB3. Nature Reviews Cancer, 2009; 9: 463-75.
[14] Hideki Yagi, Takashi Masuko. An efficient method for producing monoclonal antibodies against multi-pass membrane proteins. Yakugaku zasshi.2013 133(9) 393-945
[15] Masuko T. Analysis of target molecules towards anti-cancer therapeutic antibodies. Yakugaku Zasshi, 2021; 141: 81-92.
[16] Xinjie Lu. The Role of Large Neutral Amino Acid Transporter (LAT1) in Cancer. Curr Cancer Drug Targets. 2019 ;19(11):863-876.
[17] Ohno Y, Suda K, Masuko K, Yagi H, Hashimoto Y, Masuko T. Production and characterization of highly tumor-specific rat monoclonal antibodies recognizing the extracellular domain of human LAT1 amino-acid transporter. Cancer Science 2008; 99: 1000- 7.
[18] Masuko T, Ohno Y, Masuko K, Yagi H, Uejima S, Takechi M, Hashimoto Y. Towards therapeutic monoclonal antibodies to membrane oncoproteins by a robust strategy using rats immunized with transfectants expressing target molecules fused to green fluorescent protein. Cancer Science 2011; 102: 25-35.
[19] Nobuaki Takahashi, Rinpei Niwa, Ryousuke Nakano, et al. Strategy for technology development of antibody therapy. Folia Pharmacol. Japan. 2016, 147, 235-240.
[20] Takashi Tsuruo, Mikihiko Naito, Akihiro Tomida, et al. Molecular targeting therapy of cancer: drug resistance, apoptosis and survival signal. Cancer Sci. 2003 Jan;94(1) :15-21.
[21] Tim J Kruser, Deric L. WheelerMechanisms of resistance to HER family targeting antibodies. Exp Cell Res. 2010. 15;316(7):1083-100.
[22] Okita K, Hara Y, Okura H, et al. Anti-tumor effects of novel mAbs against cationic amino acid transporter 1 (CAT1) on human CRC with amplified CAT1 gene. Cancer Sci, 2021; 112: 563-74.
[23] Okita K, Okazaki S, Uejima S, et al. Novel functional anti-HER3 monoclonal antibodies with potent anti-cancer effects on human epithelial cancers. Oncotarget, 2020; 11: 31-45.
[24] Okita K, Imai K, Kato K, et al. Altered binding avidities and improved growth inhibitory effects of novel anti-HER3 mAb against human cancers in the presence of HER1- or HER2-targeted drugs. Biochem Biophys Res Commun, 2021; 576: 59-65.
[25] Siena S, Sartore-Bianchi A, Marsoni S, et al: Targeting the human epidermal growth factor receptor 2 (HER2) oncogene in colorectal cancer. Annals of Oncology 2018, 29 1108-1119.
[26] Fearon ER, Vogelstein B. A genetic model for colorectal tumorigenesis. Cell, 1990; 61: 759–67.
[27] Sato T, Tanigami A, Yamakawa K, et al. Allelotype of breast cancer cumulative allele losses promote tumor progression in primary breast cancer. Cancer Res, 1990; 50: 7184–9.
[28] Barnekow A, Paul E, Schartl M. Expression of the c-src protooncogene in human skin tumors. Cancer Res, 1987; 47: 235–40.
[29] Donna G Albertson. Gene amplification in cancer. Trends Genet. 2006. Aug;22(8):447-55.
[30] Ferlay J, Soerjomataram I, Dikshit R, et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer, 2015; 136: E359– 86.
[31] Arnold M, Sierra MS, Laversanne M, et al. Global patterns and trends in colorectal cancer incidence and mortality. Gut, 2017; 66: 683–91.
[32] Mampaey E, Fieeuw A, Van Laethem T, et al. Focus on 16p13.3 locus in colon cancer. PloS One, 2015; 10: e0131421.
[33] Carvalho B, Postma C, Mongera S, et al. Multiple putative oncogenes at the chromosome 20q amplicon contribute to colorectal adenoma to carcinoma progression. Gut, 2009; 58: 79–89.
[34] Diep CB, Kleivi K, Ribeiro FR, et al. The order of genetic events associated with colorectal cancer progression inferred from meta-analysis of copy number changes. Gene Chromosomes Cancer, 2006; 45: 31–41.
[35] Loo LW, Tiirikainen M, Cheng I, et al. Integrated analysis of genome-wide copy number alterations and gene expression in microsatellite stable, CpG island methylator phenotype- negative colon cancer. Gene Chromosomes Cancer, 2013; 52: 450–66.
[36] Sawada T, Yamamoto E, Suzuki H, et al. Association between genomic alterations and metastatic behavior of colorectal cancer identified by array-based comparative genomic hybridization. Gene Chromosomes Cancer, 2013; 52: 140–9.
[37] Shi ZZ, Zhang YM, Shang L, et al. Genomic profiling of rectal adenoma and carcinoma by array-based comparative genomic hybridization. BMC Med Genomics, 2012; 5: 52.
[38] Charlie C. Huang,,Yi Li,,Alex B. Lopez, et al. Temporal regulation of Cat-1 (cationic amino acid transporter-1) gene transcription during endoplasmic reticulum stress. Biochem J. 2010, Jul 1;429(1):215-24.
[39] Carvalho B, Postma C, Mongera S, et al. Multiple putative oncogenes at the chromosome 20q amplicon contribute to colorectal adenoma to carcinoma progression. Gut, 2009; 58: 79–89.
[40] Diep CB, Kleivi K, Ribeiro FR, et al. The order of genetic events associated with colorectal cancer progression inferred from meta-analysis of copy number changes. Gene Chromosomes Cancer, 2006; 45: 31–41.
[41] Loo LW, Tiirikainen M, Cheng I, et al. Integrated analysis of genome-wide copy number alterations and gene expression in microsatellite stable, CpG island methylator phenotype- negative colon cancer. Gene Chromosomes Cancer, 2013; 52: 450–66.
[42] Loo LW, Tiirikainen M, Cheng I, et al. Integrated analysis of genome-wide copy number alterations and gene expression in microsatellite stable, CpG island methylator phenotype- negative colon cancer. Gene Chromosomes Cancer, 2013; 52: 450–66.
[43] Mann GE, Yudilevich DL, Sobrevia L. Regulation of amino acid and glucose transporters in endothelial and smooth muscle cells. Physiol Rev, 2003; 83: 183–252.
[44] Closs EI, Simon A, Vékony, N, et al. Plasma membrane transporters for arginine. J Nutr, 2004; 134: 2752S-9S.
[45] Dillon BJ, Prieto VG, Curley SA, et al. Incidence and distribution of argininosuccinate synthetase deficiency in human cancers: a method for identifying cancers sensitive to arginine deprivation. Cancer, 2004; 100: 826–33.
[46] Miraki-Moud F, Ghazaly E, Ariza-McNaughton L, et al. Arginine deprivation using pegylated arginine deiminase has activity against primary acute myeloid leukemia cells in vivo. Blood, 2015; 125: 4060–8.
[47] Gerner EW, Meyskens FL Jr. Polyamines and cancer: old molecules, new understanding. Nat Rev Cancer, 2004; 4: 781–92.
[48] Fung MKL, Chan GCF. Drug-induced Amino Acid Deprivation as Strategy for Cancer Therapy. J Hematol Oncol, 2017;10: 144.
[49] Slamon DJ, Leyland-Jones B, Shak S, et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med, 2001; 344: 783–92.
[50] Piccart-Gebhart MJ, Procter M, Leyland-Jones B, et al. Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med, 2005; 353: 1659–72.
[51] Masuko T, Ohno Y, Masuko K, et al. Towards therapeutic monoclonal antibodies to membrane oncoproteins by a robust strategy using rats immunized with transfectants expressing target molecules fused to green fluorescent protein. Cancer Sci, 2011; 102: 25- 35.
[52] Ueda S, Hayashi S, Miyamoto T, et al. Anti-tumor effects of antibodies to L-type amino acid transporter 1 (LAT1) bound to human and monkey LAT1 with dual avidity modes. Cancer Sci, 2019; 110: 674-85.
[53] The cationic amino acid transporters CAT1 and CAT3 mediate NMDA receptor activation-dependent changes in elaboration of neuronal processes via the mammalian target of rapamycin mTOR pathway. Yunfei Huang, Bingnan N Kang, Jing Tian et al,. J Neurosci. 2007, Jan 17;27(3):449-58.
[54] Tsujinaka S, Soda K, Kano Y, et al. Spermine accelerates hypoxia-initiated cancer cell migration. Int J Oncol, 2011; 38: 305-312.
[55] Markowitz SD, Bertagnolli MM. Molecular origins of cancer: Molecular basis of colorectal cancer. N Engl J Med, 2009; 361: 2449–60.
[56] Amado RG, Wolf M, Peeters M, et al. Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer. J Clin Oncol, 2008; 26: 1626–34.
[57] Nicolantonio FD, Martini M, Molinari F, et al. Wild-type BRAF is required for response to panitumumab or cetuximab in metastatic colorectal cancer. J Clin Oncol, 2008; 26: 5705–12.
[58] Lièvre A, Bachet JB, Boige V, et al. KRAS mutations as an independent prognostic factor in patients with advanced colorectal cancer treated with cetuximab. J Clin Oncol, 2008; 26: 374-9.
[59] Ahmed D, Eide PW, Eilertsen IA, et al. Epigenetic and genetic features of 24 colon cancer cell lines. Oncogenesis, 2013; 2: e71.
[60] Kremer JC, Prudner BC, Lange SES, et al. Arginine Deprivation Inhibits the Warburg Effect and Upregulates Glutamine Anaplerosis and Serine Biosynthesis in ASS1-Deficient Cancers. Cell Rep, 2017; 18: 991–1004.
[61] Hara Y, Minami Y, Yoshimoto S, et al. Anti-tumor effects of an antagonistic mAb against the ASCT2 amino acid transporter on KRAS-mutated colorectal cancer cells. Cancer Med, 2020; 9: 302–12.
[62] Ueda S, Hayashi S, Miyamoto T, et al. Anti-tumor effects of antibodies to L-type amino acid transporter 1 (LAT1) bound to human and monkey LAT1 with dual avidity modes. Cancer Sci, 2019; 110: 674-85.
[63] Appert-Collin A, Hubert P, Crémel G, Bennasroune A. Role of ErbB Receptors in Cancer Cell Migration and Invasion. Front Pharmacol, 2015; 6: 283.
[64] Sweeney C, Carraway KL. Ligand discrimination by ErbB receptors: differential signaling through differential phosphorylation site usage. Oncogene, 2000 ; 19: 5568-73.
[65] Roskoski R Jr. Small molecule inhibitors targeting the EGFR/ErbB family of protein- tyrosine kinases in human cancers. Pharmacol Res, 2019; 139: 395-411.
[66] Moradi-Kalbolandi S, Hosseinzade A, Salehi M, et al. Monoclonal antibody-based therapeutics, targeting the epidermal growth factor receptor family: from herceptin to Pan HER. J Pharm Pharmacol, 2018; 70: 841-54.
[67] Sergina NV, Moasser MM. The HER family and cancer: emerging molecular mechanisms and therapeutic targets. Trends Mol Med, 2007; 13: 527-34.
[68] Shi F, Telesco SE, Liu Y, et al. ErbB3/HER3 intracellular domain is competent to bind ATP and catalyze autophosphorylation. Proc Natl Acad Sci USA, 2010; 107: 7692-7.
[69] Olayioye MA, Neve RM, Lane HA, Hynes NE. The ErbB signaling network: receptor heterodimerization in development and cancer. EMBO J, 2000; 19: 3159–67.
[70] Yarden Y. The EGFR family and its ligands in human cancer. signaling mechanisms and therapeutic opportunities. Eur J Cancer, 2001; 37: Suppl 4: S3-8.
[71] Roskoski R Jr. The ErbB/HER family of protein-tyrosine kinases and cancer. Pharmacol Res, 2014; 79: 34-74.
[72] Kalpana M, Choi BK, Huang Z, et al. Regulation of ERBB3/HER3 signaling in cancer. Oncotarget, 2014; 5: 10222–36.
[73] Montemurro F, Scaltriti M. Biomarkers of drugs targeting HER-family signalling in cancer. J Pathol, 2014; 232: 219-29.
[74] Escape from HER-family tyrosine kinase inhibitor therapy by the kinase-inactive HER3. Nature, 2007; 445: 437-41.
[75] Jura N, Shan Y, Cao X, et al. Structural analysis of the catalytically inactive kinase domain of the human EGF receptor 3. PNAS, 2009; 106: 21608-613.
[76] Citri A, Skaria KB, Yarden Y. The deaf and the dumb: the biology of ErbB-2 and ErbB-3. Exp Cell Res, 2003; 284: 54-65.
[77] Berger MB, Mendrola JM, Lemmon MA. ErbB3/HER3 does not homodimerize upon neuregulin binding at the cell surface. FEBS Lett, 2004; 569: 332–6.
[78] Burgess AW, Cho HS, Eigenbrot C, et al. An open-and-shut case? Recent insights into the activation of EGF/ErbB receptors. Mol Cell, 2003; 12: 541-52.
[79] Metzger-Filho O, Winer EP, Krop I. Pertuzumab: optimizing HER2 blockade. Clin Cancer Res, 2013; 19: 5552-6.
[80] Beji A, Horst D, Engel J, et al. Toward the prognostic significance and therapeutic potential of HER3 receptor tyrosine kinase in human colon cancer. Clin Cancer Res, 2012; 18: 956–68.
[81] Tang D, Liu CY, Shen D, et al. Assessment and prognostic analysis of EGFR, HER2, and HER3 protein expression in surgically resected gastric adenocarcinomas. Onco Targets Ther, 2014; 8: 7-14.
[82] Maurer CA, Friess H, Kretschmann B, et al. Increased expression of erbB3 in colorectal cancer is associated with concomitant increase in the level of erbB2. Hum Pathol, 1998; 29: 771–7.
[83] Zhang N, Chang Y, Rios A, An Z. HER3/ErbB3, an emerging cancer therapeutic target. Acta Biochim Biophys Sin (Shanghai), 2016; 48: 39-48.
[84] Yang L, Li Y, Shen E, et al. NRG1-dependent activation of HER3 induces primary resistance to trastuzumab in HER2-overexpressing breast cancer cells. Int J Oncol, 2017; 51: 1553-62.
[85] Garrett JT, Olivares MG, Rinehart C, Granja-Ingram ND, Sanchez V, Chakrabarty A, et al. Transcriptional and posttranslational up-regulation of HER3 (ErbB3) compensates for inhibition of the HER2 tyrosine kinase. Proc Natl Acad Sci U S A, 2011;108(12):5021–6.
[86] Gala K, Chandarlapaty S. Molecular Pathways: HER3 targeted therapy. Clin Cancer Res, 2014; 20: 1410-6.
[87] Mota JM, Collier KA, Costa RLB, et al. A comprehensive review of heregulins, HER3, and HER4 as potential therapeutic targets in cancer. Oncotarget, 2017; 8: 89284-306.
[88] Masuko T, Ohno Y, Masuko K, et al. Towards therapeutic monoclonal antibodies to membrane oncoproteins by a robust strategy using rats immunized with transfectants expressing target molecules fused to green fluorescent protein. Cancer Sci, 2011; 102: 25- 35.
[89] Yuan Q, Furukawa T, Tashiro T, et al. Immuno-PET imaging of HER3 in a model in which HER3 signaling plays a critical role. PLoS ONE, 2015; 10: e0143076.
[90] Piulats JM, Kondo J, Endo H, et al. Promotion of malignant phenotype after disruption of the three-dimensional structure of cultured spheroids from colorectal cancer. Oncotarget, 2018; 9: 15968-83.
[91] Sergina NV, Rausch M, Wang D, et al. Escape from HER-family tyrosine kinase inhibitor therapy by the kinase-inactive HER3. Nature, 2007; 445: 437-41.
[92] Amin DN, Campbell MR, Moasser MM. The role of HER3, the unpretentious member of the HER family, in cancer biology and cancer therapeutics. Semin Cell Dev Biol, 2010; 21: 944–50.
[93] Gaborit N, Abdul-Hai A, Mancini M, et al. Examination of HER3 targeting in cancer using monoclonal antibodies. Proc Natl Acad Sci USA, 2015; 112: 839–44.
[94] Hervent AS, De Keulenaer GW. Molecular mechanisms of cardiotoxicity induced by ErbB receptor inhibitor cancer therapeutics. Int J Mol Sci, 2012; 13: 12268–86.
[95] Sakai K, Yokote H, Murakami-Murofushi K, et al. Pertuzumab, a novel HER dimerization inhibitor, inhibits the growth of human lung cancer cells mediated by the HER3 signaling pathway. Cancer Sci, 2007; 98: 1498-503.
[96] Li C, Brand TM, Iida M, et al. Human epidermal growth factor receptor 3 (HER3) blockade with U3 1287/AMG888 enhances the efficacy of radiation therapy in lung and head and neck carcinoma. Discov Med, 2013; 16: 79–92.
[97] Malm M, Frejd FY, Stahl S, Lofblom J. Targeting HER3 using mono- and bispecific antibodies or alternative scaffolds. MAbs, 2016; 8: 1195–209.
[98] Ohno Y, Suda K, Masuko K, et al. Production and characterization of highly tumor- specific rat monoclonal antibodies recognizing the extracellular domain of human LAT1 amino-acid transporter. Cancer Sci, 2008; 99: 1000-7.
[99] Gullick WJ. The c-erbB3/HER3 receptor in human cancer. Cancer Surv, 1996; 27: 339- 49.
[100] Ocana A, Vera-Badillo F, Seruga B, et al. HER3 overexpression and survival in solid tumors: a meta-analysis. J Natl Cancer Inst, 2013; 105: 266-73.
[101] Rodrigo G B Cruz, Stephen F Madden, Cathy E Richards, et al. Human Epidermal Growth Factor Receptor-3 Expression Is Regulated at Transcriptional Level in Breast Cancer Settings by Junctional Adhesion Molecule-A via a Pathway Involving Beta-Catenin and FOXA1. Cancers. 2021. Feb 19;13(4):871.
[102] Chen Zhao, Funian Lu, Hongxia Chen, et al. Dysregulation of JAM-A plays an important role in human tumor progression. Int J Clin Exp Pathol. 2014; 7(10):7242-48
[103] Tonegawa S. Somatic generation of antibody diversity. Nature, 1983; 302: 575–81.
[104] Patten PA, Gray NS, Yang PL, et al. The immunological evolution of catalysis. Science, 1996; 271: 1086–91.
[105] Schultz PG, Yin J, Lerner RA. The chemistry of the antibody molecule. Angew Chem Int Ed Engl, 2002; 41: 4427-37.
[106] Collins AM, Sewell WA, Edwards MR. Immunoglobulin gene rearrangement, repertoire diversity, and the allergic response. Pharmacol Ther, 2003;100: 157-70.
[107] LoRusso P, Janne PA, Oliveira M, et al. Phase I study of U3-1287, a fully human anti- HER3 monoclonal antibody, in patients with advanced solid tumors. Clin Cancer Res 2013;19(11):3078–87.
[108] Kiavue N, Cabel L, Melaabi S, et al. ERBB3 mutations in cancer: biological aspects, prevalence and therapeutics. Oncogene, 2020; 39: 487-502.
[109] Re MD, Cucchiara F, Petrini I, et al. erbB in NSCLC as a molecular target: current evidences and future directions. ESMO Open, 2020; 5: e000724.
[110] Sforza V, Martinelli E, Ciardiello F, et al. Mechanisms of resistance to anti -epidermal growth factor receptor inhibitors in metastatic colorectal cancer. World J Gastroenterol, 2016; 22: 6345-61.
[111] Hayashi N, Yamasaki A, Ueda S, et al. Oncogenic transformation of NIH/3T3 cells by the overexpression of L-type amino acid transporter 1, a promising anti-cancer target. Oncotarget, 2021; 12: 1256-70.
[112] Asao H, Takeshita T, Ishii N, et al. Reconstitution of functional interleukin 2 receptor complexes on fibroblastoid cells: involvement of the cytoplasmic domain of the gamma chain in two distinct signaling pathways. Proc Natl Acad Sci USA, 1993; 90: 4127-31.
[113] Pillet AH, Juffroy O, Mazard-Pasquier V, et al. Human IL-Rβ chains form IL-2 binding homodimers. Eur Cytokine Netw, 2008; 19: 49-59.
[114] Baselga J, Swain SM. Novel anticancer targets: Revisiting ERBB2 and ERBB3. Nature Reviews Cancer, 2009; 9: 463-75.
[115] Saito Y, Soga T. Amino acid transporters as emerging therapeutic targets in cancer. Cancer Sci, 2021; 112: 2958-65.
[116] Goydel RS, Rader C. Antibody-based cancer therapy. Oncogene, 2021; 40: 3655-64.
[117] Fellouse, F.A., Wiesmann, C., & Sidhu, S.S. Proc. Natl.Acad. Sci. USA. 2004. 101, 12467
[118] Fellouse, F.A., Li, B., Compaan, D.M., Peden, A.A., Hymowitz, J. Mol. Biol. 2005. 348, 1153
[119] Lim SM, Kim CG, Lee JM, et al. Patritumab Deruxtecan: Paving the way for EGFR- TKI-resistant NSCLC. Cancer Discovery, 2022; 12: 16-19.
[120] Nakada T, Sugihara K, Jikoh T, et al. The latest research and development into the antibody-drug conjugate, [fam-] Trastuzumab Deruxtecan (DS-8210a), for HER2 cancer therapy. Chem Pharm Bull, 2019; 67: 173-85.
[121] Okazaki S, Nakatani F, Masuko K, et al. Development of an ErbB4 monoclonal antibody that blocks neuregulin-1-induced ErbB4 activation in cancer cells. Biochem Biophys Res Commun, 2016; 470: 239-44.
[122] Yoshioka T, Nishikawa Y, Ito R, et al. Significance of integrin αvβ5 and erbB3 in enhanced cell migration and liver metastasis of colon carcinomas stimulated by hepatocyte- derived heregulin. Cancer Sci, 2010; 101: 2011-8.
[123] Kopp-Kubel S. International Nonproprietary Names (INN) for pharmaceutica substances. Bull World Health Organ, 1995; 73: 275-9.
[124] Kopp-Kubel S. International Nonproprietary Names (INN) for pharmaceutica substances. Bull World Health Organ, 1995; 73: 275-9.
[125] Ye J, Ma N, Madden TL, Ostell JM. IgBLAST: an immunoglobulin variable domain sequence analysis tool. Nucleic Acids Res, 2013; 41, W34-40.
[126] Hara Y, Torii R, Ueda S, et al. Inhibition of tumor formation and metastasis by a monoclonal antibody against lymphatic vessel endothelial hyaluronan receptor 1. Cancer Sci, 2018; 109: 3171–82.
[127] Nishimura T, Nakamura Y, Tsukamoto H, et al. Human c-erbB-2 proto-oncogene product as a target for bispecific-antibody-directed adoptive tumor immunotherapy. Int J Cancer, 1992; 50: 800-4.
[128] Kato K. A novel screening method to establish tumor-targeting antibodies reliable for drug delivery system. Yakugaku Zasshi, 2013; 133: 931-8.
[129] Chou TC, Talalay P. Quantitative analysis of dose-effect relationship: The combined effects of multiple drugs or enzyme inhibitors. Adv Enzyme Regul, 1984; 22: 27-55.